Anti-Human Epidermal Growth Factor Receptor 2 therapies in metastatic colorectal cancer: a systematic review and meta-analysis Authors: Simone Rota, Paola Di Nardo, Emma Zottarelli, Fabiola Giudici, Riccardo Vida, Miriam Zilli, Marco de Scordilli, Luisa Foltran, Arianna Fumagalli, Michela Guardascione, Elena Ongaro, Fabio Puglisi Published: 2026 ABSTRACT AbstractBackgroundHER2 amplification identifies a subgroup of colorectal cancer with poorer prognosis and resistance to anti-EGFR therapy. We conducted a systematic review and a meta-analysis of available data on anti-HER2 treatments (HER2Tx) in mCRC patients (pts).MethodsA systematic literature search was performed, encompassing phase II/III clinical trials (CTs) investigating HER2Tx in HER2-overexpressed mCRC. CTs reporting HER2Tx plus chemotherapy were excluded. Primary endpoints were objective response rate (ORR) and disease control rate (DCR). Fixed and random-effect models were applied according to heterogeneity assessed through I 2 statistics. Progression-free survival (PFS) and overall survival (OS) were compared descriptively and pooled using the weighted median of medians (WM) with approximated 95% CIs. Subgroup analyses by HER2Tx were carried out.ResultsThe analysis included 10 CTs evaluating Trastuzumab-Pertuzumab (T + P, 5 CTs,), Trastuzumab Deruxtecan (T-DXd, 2 CTs), Trastuzumab-Lapatinib (T + L, 1 CT), Pertuzumab-TDM1 (P+TDM1, 1 CT), and Trastuzumab-Tucatinib (T-Tu, 1 CT), for a total of 467 pts. The pooled ORR was 33.7% (29.6%-38.1%), and the pooled DCR was 68.5% (58.1%-77.4%). The WM OS was 13.4 months (10-24.1) and WM PFS was 5.5 months (4.1-6.9). The T-DX and T-Tu groups showed higher ORR and DCR (38% and 39% respectively, 85.1% and 73.2% respectively) compared to the T + P group (ORR, 30%; DCR, 52.6%).ConclusionsHER2Tx demonstrated efficacy in pretreated CRC pts, exhibiting good DCR and ORR alongside promising PFS and OS. T-DXd and T-Tu appear to outperform T + P; however, further studies are needed.Keywords: colorectal cancer, HER2, HER2 therapies, metastatic This meta-analysis indicates that anti-HER2 agents are effective in treating advanced HER2-positive colorectal cancer. Notably, enhanced efficacy was observed in the MOUNTAINEER trial, which assessed tucatinib combined with trastuzumab, as well as in DESTINY CRC 01/02, which evaluated trastuzumab deruxtecan. These regimens appear to surpass the traditional dual blockade of trastuzumab and pertuzumab. Additionally, trastuzumab deruxtecan has demonstrated efficacy in KRAS-mutated colorectal cancer and shows a favorable safety profile. It is therefore crucial that HER2 status be assessed in advanced colorectal cancer in order to have access to highly effective treatments, particularly compared to traditional chemotherapy, leading to improved patient outcomes. Introduction Colorectal cancer (CRC) is the third most common cancer in both sexes and the second leading cause of cancer-related mortality worldwide, according to GLOBOCAN estimates.1 Approximately 15% to 30% of patients are diagnosed with de novo metastatic CRC (mCRC), while 20% to 50% of those initially presenting with localized disease eventually develop distant metastases.2 First-line systemic therapy typically combines a fluoropyrimidine-based chemotherapy (CT) backbone with oxaliplatin and/or irinotecan plus monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF). Treatment choice depends on the patient’s performance status (PS), the sidedness of the primary tumor (right vs left), and the molecular profile (BRAF, KRAS, and NRAS status).2–4 Around 5% of mCRC cases are characterized by mismatch repair deficiency/microsatellite instability (dMMR/MSI-H), and benefit from immune checkpoint inhibitors (ICIs)-based therapy.2–5 Among emerging biomarkers, Human Epidermal growth factor Receptor 2 (HER2) is emerging as a potential predictive and prognostic factor. Unlike other ERBB family members, HER2 lacks a ligand-binding domain and is activated through heterodimerization with other ligand-bound ERBB receptors.6–8 Notably, HER2 alterations, including overexpression, amplification ,and mutations, play a significant biological role and have diagnostic, prognostic, and therapeutic implications across several malignancies in breast, gastric, lung, and colorectal cancer.9 In mCRC, ERBB2 gene alterations are detected in approximately 3%-5% of cases.10 Activating point mutations occur in 1%-3%; both alterations may coexist in up to 20% of patients.11–13 Several studies have also reported that left-sided colon cancers and rectal cancers are more likely to harbor HER2 or EGFR alterations.14,15 HER2 status is usually assessed by immunohistochemistry (IHC) for protein expression, in situ hybridization (ISH) for gene amplification, or DNA sequencing for ERBB2 amplifications.9 Anti-HER2 agents are established treatments for HER2-positive breast and gastric cancers, and their role in metastatic colorectal cancer (mCRC) has been increasingly investigated. The HERACLES-A trial16 first demonstrated the efficacy of trastuzumab plus lapatinib, followed by subsequent studies evaluating various combinations, including trastuzumab with pertuzumab (HERACLES-B, MyPathway, TRIUMPH, TAPUR), trastuzumab with tucatinib (MOUNTAINEER), and trastuzumab deruxtecan (T-DXd) in the DESTINY-CRC01/02 trials. These phase II studies showed encouraging antitumor activity and manageable safety profiles17–23 (Table 1). Table 1.Trials summary.TrialPatientsNumber of previous linesDefinition of HER2 positivityTreatment regimen TAPUR 281-3Amplification on NGSTrastuzumab + pertuzumab MyPATHWAY 571-9, 4 median prior linesFluorescence/chromogenic in situ hybridization (FISH/CISH; HER2 amplification based on HER2/CEP17 ratio >2·0 or HER2 copy number >6·0), next- generation sequencing (NGS; HER2 amplification based on copy number gain), and/or immunohistochemistry (IHC; HER2 overexpression based on IHC 3+ staining).Trastuzumab + pertuzumab HERACLES-A 275 (4-6)3+ HER2 score in more than 50% of cells by immunohistochemistry or with 2+ HER2 score and a HER2: CEP17 ratio higher than 2 in more than 50% of cells by FISHTrastuzumab + lapatinib HERACLES-B 313 (3-5)3+ HER2 score in more than 50% of cells by immunohistochemistry or with 2+ HER2 score and a HER2: CEP17 ratio higher than 2 in more than 50% of cells by FISHTrastuzumab + TDM-1 DRUP 27 3 HER2 positivity was defined as at least 7 copies of HER2, as estimated by panel-based Next Generation Sequencing (NGS), WGS or In Situ HybridizationTrastuzumab + pertuzumab SWOG S1613 541-2IHC 3+ or 2+ and ISH amplified (dual-probe HER2/CEP17 ratio >2.0).Trastuzumab and pertuzumab DESTINY CRC 01 864 (2–11)immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+Trastuzumab deruxtecan DESTINY CRC 02 1223-4Immunohistochemistry score of 3+ or 2+ with HER2 amplification identified by in-situ hybridizationTrastuzumab deruxtecan MOUNTAINEER 1172Score of 3+ by immunohistochemistry, 2+by immunohistochemistry plus amplification by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH), or amplification by next-generation sequencing.Trastuzumab—tucatinib TRIUMPH 30≥3IHC 3+ or FISH positive (HER2/CEP17 ratio ≥2.0)Trastuzumab and pertuzumab Trials summary. Based on these findings, NCCN guidelines now recommend 4 anti-HER2 regimens for HER2-positive mCRC: trastuzumab plus lapatinib, trastuzumab plus pertuzumab, trastuzumab plus tucatinib, and T-DXd.4 However, all supporting studies are phase II trials with limited sample sizes, and no phase III data are yet available. Despite recent NCCN updates, specific treatment guidelines for anti-HER2 therapy in mCRC remain lacking in Europe. The aim of this metanalysis is to summarize the available data from clinical trials investigating anti-HER2 therapies in mCRC, assess the overall effectiveness of the different treatment strategies, and identify patient subgroups most likely to benefit from these targeted approaches. Methods Search strategy and data extraction A systematic review of the literature on patients with HER2-amplified mCRC treated with anti-HER2 agents was conducted. The electronic databases MEDLINE (via PubMed), Embase (via OVID), and the Cochrane Central Register of Clinical Trials (CENTRAL, via Wiley) were systematically searched from January 1, 2012, to November 30, 2024. The search strategy focused on the following MeSH terms and keywords: (“colorectal” OR “colon”) AND “cancer” AND (“metastatic” OR “advanced”) AND (“HER2” OR “ERBB2”) AND (“treatment” OR “therapy”). The review adhered to the Cochrane Collaboration’s guidelines to ensure comprehensive identification of relevant clinical trials. In case of duplicate publications, only the most recent and complete reports were included. Phase II/III randomized clinical trials were considered, including both full-text articles and abstracts for which full text was available (Figure 1). Consort diagram. This review has been submitted for registration with the PROSPERO Editorial Board (ID CRD42025632144), https://www.crd.york.ac.uk.prospero/, accessed on January 13, 2025. Eligible studies included phase II/III trials evaluating combinations of anti-HER2 therapies compared to other late-line treatment regimens. Exclusion criteria were non-English publications, editorials, reviews, and real-world evidence. An initial screening based on titles and abstracts was conducted by 2 independent reviewers (S.R. and E.Z.). Data extraction was also independently performed by the same reviewers (S.R. and E.Z.), and a third investigator (P.D.N.) verified the extracted data. Discrepancies were resolved through consensus. Clinical outcomes of interest were: Overall response rate (ORR): percentage of patients achieving a partial (PR) or complete response (CR), per RECIST 1.1 criteria. Overall response rate (ORR): percentage of patients achieving a partial (PR) or complete response (CR), per RECIST 1.1 criteria. Disease control rate (DCR): percentage of patients with tumor response or stable disease (SD). Disease control rate (DCR): percentage of patients with tumor response or stable disease (SD). Progression-free survival (PFS): time from randomization to disease progression or death, whichever occurred first. Progression-free survival (PFS): time from randomization to disease progression or death, whichever occurred first. Overall survival (OS): time from randomization to death from any cause. Overall survival (OS): time from randomization to death from any cause. Following the title/abstract screening, 17 of 73 PubMed records, 34 of 461 Embase studies, and 19 of 137 Cochrane records were selected. After removing duplicates, 30 full-text articles were evaluated. Sixteen were excluded due to use of chemotherapy or non-anti-HER2 agents, and 4 trials were closed due to poor accrual. Ultimately, 10 clinical trials were included in the analysis: TAPUR, MyPATHWAY, HERACLES, HERACLES-B, MOUNTAINEER, DESTINY-CRC 01, DESTINY-CRC 02, TRIUMPH, DRUP, and SWOG S1613. Data analysis This meta-analysis was conducted using the “meta” and “metamedian” packages in R version 4.2.3 (R Core Team, 2023), R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (https://www.R-project.org/). The primary endpoints were ORR and DCR. Fixed and random-effect models were applied based on the degree of heterogeneity, as assessed through Cochran’s Q test and I2 statistic. Given the inclusion of single-arm studies, for which hazard ratios (HR) are not applicable, treatment effectiveness was evaluated through descriptive comparisons of secondary endpoints. Specifically, we focused on PFS and OS as critical indicators of treatment efficacy. We pooled the medians of these outcomes using the methodology proposed by McGrath et al.,24 which includes both the median of medians (MM) and the weighted median of medians (WM). The weights were proportional to the number of patients in each study and normalized to sum to 1. This method has demonstrated superior accuracy compared to transformation-based approaches that estimate the sample mean and variance from median data. Approximate 95% confidence intervals were calculated for both the pooled medians and the weighted pooled medians using the metamedian package in R. Subgroup analyses were also performed to assess differences in treatment effectiveness according to the specific anti-HER2 therapy administered, thereby providing further insight into the relative effectiveness of different therapeutic strategies. To evaluate the risk of bias, we applied Peters’ regression test, which assesses the association between effect size and standard error. In addition, funnel plots were used as a visual tool to detect potential publication bias among the included studies. Results A total of 502 patients from 10 clinical trials (TAPUR, MyPATHWAY, HERACLES, HERACLES-B, MOUNTAINEER, DESTINY-CRC 01, DESTINY-CRC 02, TRIUMPH, DRUP, and SWOG S1613) were included in this analysis. The primary endpoints were ORR and DCR, while secondary endpoints included OS and PFS. Across all included studies, anti-HER2 therapies demonstrated encouraging activity in pretreated mCRC patients. The pooled ORR was 33.7% (95% CI, 29.6%-38.1%) and the pooled DCR was 68.5% (95% CI, 58.1%-77.4%). Among the evaluated regimens, the tucatinib-based combination (from the MOUNTAINEER trial) yielded interesting efficacy, especially compared to the trastuzumab pertuzumab group, with an ORR of 39% and a DCR of 73.1%. However, these results are based on a single trial, and should be interpreted with caution. The most extensive studies involved dual HER2 blockade or T-DXd. The T-DXd group showed numerically superior outcomes, with an ORR of 38% and a DCR of 85.1%, compared to trastuzumab plus pertuzumab, which achieved an ORR of 30% and a DCR of 52.6% (Figures 2 and 3). Pooled ORR was 33.7% (95% CI, 29.6%-38.1%). Pooled DCR was 68.5% (95% CI, 58.1%-77.4%). We used Peter’s test for risk of bias detection across the studies, which revealed no funnel plot asymmetry (P = .050) and (P = .231), suggesting no significant bias (Figures S1 and S2, see online supplementary material for a color version of these figures). 502 patients were evaluated for PFS and 445 for OS. The weighted median PFS was 5.5 months (4.1-6.9), and the weighted median OS was 13.4 months (10.1-4.1) (Tables 2 and 3). Table 2.Weighted median PFS.StudySample sizeMedian PFS (95% CI)Median follow-up (months)Anti-HER2 TAPUR 284.4 (2.8-6.9)23.5TRASTUZUMAB PERTUZUMAB MyPATHWAY 572.9 (1.4-5.3)7.3TRASTUZUMAB PERTUZUMAB TRIUMPH_Tissue 274.0 (1.4-5.6)9.2TRASTUZUMAB PERTUZUMAB TRIUMPH_ct-DNA 253.1 (1.4-5.6)7.6TRASTUZUMAB PERTUZUMAB DRUP 244.3 (1.9-10.3)6.4TRASTUZUMAB PERTUZUMAB SWOG S16S13 264.4 (1.9-7.6)NATRASTUZUMAB PERTUZUMAB DESTINY CRC-01 536.9 (4.1-8.7)14.4TRASTUZUMAB DERUXTECAN DESTINY CRC-02_CohortA 405.5 (4.2-7.0)10.3TRASTUZUMAB DERUXTECAN DESTINY CRC-02_CohortB 825.8 (4.6-7.0)8.9TRASTUZUMAB DERUXTECAN HERACLES 275.3 (4.0-8.0)23.5TRASTUZUMAB LAPATINIB HERACLES-B 314.1(3.6-5.9)7.7PERTUZUMAB T-DM1 MOUNTAINEER 828.2 (4.2-7.0)16.3TRASTUZUMAB TUCATINIB Weighted median PFS 502 5.5 (4.1-6.9) Weighted median PFS. Table 3.Weighted median OS.StudySample sizeMedian OS (95% CI)Median follow-up (months)Anti-HER2 TAPUR 2815 (8.0-25.6)23.5TRASTUZUMAB PERTUZUMAB MyPATHWAY 5711.5 (7.7-Na)7.3TRASTUZUMAB PERTUZUMAB TRIUMPH_Tissue 2710.1(4.5-16.5)9.2TRASTUZUMAB PERTUZUMAB TRIUMPH_ct-DNA 258.8 (4.3-12.9)7.6TRASTUZUMAB PERTUZUMAB DRUP 248.2 (7.2-14.7)6.3TRASTUZUMAB PERTUZUMAB DESTINY CRC-01 5315.5 (8.8-20.8)14.4TRASTUZUMAB DERUXTECAN DESTINY CRC-02_CohortA 40Not reached10.3TRASTUZUMAB DERUXTECAN DESTINY CRC-02_CohortB 8213.4 (Na-Na)8.9TRASTUZUMAB DERUXTECAN HERACLES 2711.5 (8.3-17.0)23.5TRASTUZUMAB LAPATINIB MOUNTAINEER 8224.1 (20.3-36.7)16.3TRASTUZUMAB TUCATINIB Weighted median OS 445 13.4 (10.1-24.1) Weighted median OS. The subgroup analysis confirmed the superior efficacy of the tucatinib-based regimen compared to the classic dual blockade strategies, with a PFS of 8.2 months and a median OS of 24.1 months. Similarly, T-DXd demonstrated improved outcomes compared to trastuzumab plus pertuzumab, both in terms of OS (14.5 vs 11.4 months) and PFS (5.8 vs 4.0 months) (Table 4). Table 4.Subgroup OS and PFS analysis according to anti-HER2 treatment.Anti-HER2No of studiesWeighted median PFS (95% CI) TRASTUZUMAB PERTUZUMAB 64.0 (3.1-4.4) TRASTUZUMAB DERUXTECAN 35.8 (5.5-6.9) TRASTUZUMAB LAPATINIB 15.3 (4.0-8.0) PERTUZUMAB T-DM1 14.1(3.6-5.9) TRASTUZUMAB TUCATINIB 18.2 (4.2-7.0)Anti-HER2No of studiesWeighted median OS (95% CI) TRASTUZUMAB PERTUZUMAB 511.4 (8.2-15.0) TRASTUZUMAB DERUXTECAN 214.5 (13.4-15.5) TRASTUZUMAB LAPATINIB 111.5 (8.3-17.0) TRASTUZUMAB TUCATINIB 124.1 (20.3-36.7) Subgroup OS and PFS analysis according to anti-HER2 treatment. Compared to standard therapies in late lines, the dual blockade with different anti-HER2 therapies showed fewer severe adverse events grade≥3 (38% in MOUNTAINEER trial, 37% in My Pathway trial, at least 5% in HERACLES-A trial and 11% in the TAPUR trial). The issue is similar for trastuzumab deruxtecan, which was evaluated in DESTINY- CRC 01 and 02 trials. Particularly, in DESTINY CRC-02, drug-related serious adverse events occurred in 42.2% of the patients treated at 5.4 mg/kg vs 48.7% at 6.4 mg/kg, with drug-related ILD occurring in 9.6% (2 grade 1; 6 grade 2) at 5.4 mg/kg vs 17.9% at 6.4 mg/kg and 2 drug-related deaths (1 in 5.4 mg/kg and 1 in 6.5 mg/kg). Discussion CRC remains one of the leading causes of cancer-related mortality worldwide, with a rising incidence in Western countries, thus representing a growing global health concern. Approximately 20% of patients are diagnosed with de novo metastatic disease. While chemotherapy continues to represent the cornerstone of treatment in the advanced setting, there is a growing emphasis on identifying actionable molecular targets, to improve patient selection and to define subgroups that may benefit from targeted therapy. Within this context, HER2 overexpression and amplification have emerged as a promising biomarker. Notably, only a subset of patients is eligible for HER2-targeted therapy. This includes individuals with strong HER2 protein expression, defined as IHC 3+, as well as those with IHC 2+ who demonstrate HER2 gene amplification by FISH.2 Encouraging ORRs have been observed in patients receiving HER2-targeted therapies, supporting the potential role of anti-HER2 strategies in this molecularly defined subgroup. The first trial to demonstrate a benefit in terms of ORR and DCR with anti-HER2 drugs in heavily pretreated patients with mCRC was the HERACLES-A, which investigated the combination of trastuzumab and lapatinib, reporting an ORR of 30% and a DCR of 59%.16 Building on these results, the HERACLES-B trial evaluated the combination of trastuzumab emtansine (T-DM1) and pertuzumab in RAS/BRAF wild-type and HER2-positive mCRC. However, the study did not meet the primary endpoint, which was an ORR of at least 30%.17 The dual blockade with trastuzumab and pertuzumab was subsequently explored in the MyPathway, TRIUMPH, and TAPUR trials. In these studies, clinical activity was confirmed, with ORRs of 32%, 30%, and 25%, and DCRs of 44%, 54%, and 67%, respectively.18–20 The combination of trastuzumab and tucatinib was assessed in the MOUNTAINEER trial, demonstrating clinically meaningful antitumor activity along with a favorable safety profile (ORR, 38.1%; DCR, 71%).21 Finally, the phase II DESTINY-CRC01 and DESTINY-CRC02 studies evaluated the activity of trastuzumab deruxtecan (T-DXd) in patients with refractory RAS/BRAF wild-type, HER2-positive mCRC, reporting promising results in terms of DCR and ORR (ORR, 38%; DCR, 85.1%). Our meta-analysis confirmed the clinical activity of anti-HER2 therapies in pretreated patients with mCRC. The pooled ORR was 33.7% (95% CI, 29.6%-38.1%) and the pooled DCR was 68.5% (95% CI, 58.1%-77.4%). Although direct comparisons are not feasible, when evaluating outcome measures such as PFS and OS, anti-HER2-based regimens appear to provide superior results compared to standard third-line therapies, such as trifluridine/tipiracil plus bevacizumab (as reported in the SUNLIGHT trial) or regorafenib.25,26 However, most studies have a follow-up of less than 1 year (OS data may not yet be mature). Targeted therapies have therefore demonstrated not only better response rates, but are also well tolerated, with a better toxicity profile. In fact, compared to standard therapies as mentioned above (in which severe adverse events grade ≥ 3 were reported in 74% of patients in the SUNLIGHT trial and in 54% of patients in the CORRECT trial with regorafenib), the dual blockade with different anti HER2 therapies showed fewer severe adverse events grade ≥ 3 (38% in the MOUNTAINEER trial, 37% in the My Pathway trial, at least 5% in the HERACLES-A trial, and 11% in the TAPUR trial). The issue is similar for trastuzumab deruxtecan, which was evaluated in DESTINY- CRC 01 and 02 trials. Particularly, in DESTINY CRC-02, drug-related serious adverse events occurred in 42.2% of the patients treated at 5.4 mg/kg vs 48.7% at 6.4 mg/kg, with drug-related ILD occurring in 9.6% (2 grade 1; 6 grade 2) at 5.4 mg/kg vs 17.9% at 6.4 mg/kg and 2 drug-related deaths (1 in 5.4 mg/kg and 1 in 6.5 mg/kg).23 Among the regimens analyzed, the tucatinib plus trastuzumab combination showed the most favorable efficacy data (ORR, 38.1%; DCR 71%), although this evidence is derived from a single study (MOUNTAINEER), along with trastuzumab deruxtecan. The most extensively studied strategies remain dual HER2 blockade and T-DXd. T-DXd achieved excellent outcomes among all anti-HER2 regimens evaluated, with an ORR of 38% and a DCR of 85.1%, outperforming the trastuzumab + pertuzumab group (ORR, 30%; DCR, 52.6%) in terms of both response rates and survival endpoints (PFS and OS). It is important to highlight that, patients enrolled in these trials were heavily pretreated, with a median of 4 prior lines of therapy. All trials excluded patients previously treated with anti-HER2 agents, except for the DESTINY-CRC studies. Notably, T-DXd maintained clinical activity in this subgroup although, as expected, ORR, PFS, and OS were numerically lower in patients not naïve to HER2-targeted therapies. In the DESTINY-CRC 02 study, RAS or RAF mutations were included, but most tumors were RAS wild-type; 83% and 85% in the 5.4 mg/kg group and 6.4 mg/kg group, respectively. While HER2-positive RAS-mutated CRC does not appear to have meaningful response to dual HER2-targeted therapy, such tumors may still be sensitive to trastuzumab deruxtecan. In fact, activity was observed irrespective of RAS status, suggesting that HER2 amplification may serve as a dominant therapeutic driver even in patients with RAS-mutant tumors.23 Our study has some limitations: first, the analysis was based on published data and was constrained by the limited availability of individual patient-level information. Furthermore, the small number of patients and the heterogeneity of the therapeutic strategies preclude definitive conclusions regarding the optimal sequencing or selection of anti-HER2 therapies. Nevertheless, trastuzumab plus tucatinib and trastuzumab deruxtecan consistently demonstrated superior clinical activity compared to conventional dual blockade with trastuzumab and pertuzumab, particularly in terms of ORR and DCR. Nevertheless, all the different anti-HER2 combinations evaluated in mCRC appear promising, except for the HERACLES-B trial, which investigated the combination of trastuzumab and T-DM1 and failed to meet its primary endpoint.17 Unlike in breast and gastric cancers, for mCRC patients, the majority of anti-HER2 regimens have been studied without a conventional chemotherapy backbone. Some early-phase trials, combining anti-HER2 agents with chemotherapy, yielded disappointing results, ultimately leading to the abandonment of this strategy.27 Further research on possible synergistic combinations is warranted. In this context, results from the MOUNTAINEER-03 trial, which is evaluating tucatinib and trastuzumab in combination with chemotherapy, are highly anticipated.28 It is also essential that future trials be carefully designed, with appropriate comparator arms. For instance, the SWOG 1613 trial compared trastuzumab plus pertuzumab to cetuximab plus irinotecan, a combination that may be considered suboptimal in HER2-amplified tumors, due to their intrinsic resistance to anti-EGFR therapies. It is evident that, despite the enthusiasm generated by the promising results from the available trials, several challenges remain to be addressed. A major issue concerns the lack of standardization in the definition of HER2-positivity, and the need to better characterize the population most likely to benefit from HER2-targeted strategies. In the HERACLES-A and HERACLES-B trials, tumors were considered HER2-positive if they exhibited an IHC score of 3+, or 2+ with HER2 gene amplification in at least 50% of tumor cells.29 In contrast, other studies such as MyPathway, TRIUMPH, and DESTINY-CRC, applied HER2 scoring criteria based on those used in gastric cancer. Although the small sample sizes in these studies prevent definitive conclusions, this heterogeneity in HER2 assessment methods introduces potential sources of bias.27 For instance, in the TRIUMPH study, circulating tumor DNA (ctDNA) was used to detect HER2 amplification; notably, however, none of the 3 patients who tested positive for HER2 amplification by ctDNA, but lacked tissue IHC confirmation, responded to treatment. Similarly, in the MyPathway trial, no ORRs were observed in patients with HER2-amplification in the absence of protein overexpression. To reduce potential discrepancies, some trials adopted normalization strategies for HER2 amplification levels. Nonetheless, the presence of amplification alone may not be sufficient to establish HER2 as a true oncogenic driver. From a biological perspective, amplification without corresponding transcription and protein expression may lack clinical significance. Therefore, IHC-based detection of HER2 overexpression may offer a more accurate means of identifying patients who are most likely to benefit from HER2-directed therapies. Efforts to optimize HER2 assessment also include liquid biopsy approaches, as shown in the translational analyses of the DESTINYCRC-01 trial. In that study, multiple biomarkers were assessed in plasma, including HER2-overexpression and amplification have adjusted for copy number, as well as levels of HER2 extracellular domain (HER2ECD) measured by enzyme-linked immunosorbent assay (ELISA). These methods yielded to consistent results among patients with confirmed responses. However, it remains unclear whether this concordance is due the choice of biomarker, or rather to the mechanism of action of T-DXd itself. HER2-amplification has been recognized as a mechanism of resistance to anti-EGFR therapies, similar to what is observed with KRAS, NRAS, and BRAF mutations.27,30 Likewise, ERBB2 mutations have also been identified as contributors to resistance against anti-EGFR agents.15 In addition, ORR, PFS, and OS reported in the trials included in our meta-analysis were consistently lower in patients with tumors harboring KRAS mutations, suggesting a potential negative predictive role for KRAS in the context of anti-HER2 treatment. HER2-positive tumors may exhibit a hybrid biological profile, lying somewhere between all-wt tumors, which are typically responsive to anti-EGFR agents, and KRAS-mutant tumors, which are usually resistant. Most studies evaluating anti-HER2 strategies required KRAS-wt status for inclusion, and the occurrence of co-alterations (eg, HER2 amplification plus KRAS mutation) appears to be rare. However, a recent biopsy, obtained immediately prior to the initiation of HER2-targeted therapy, was not always available. In the TRIUMPH trial, which incorporated both tissue and liquid biopsies, mutational analyses revealed a higher incidence of RTK/RAS/PI3K pathway alterations in ctDNA from non-responders, compared to matched tissue samples collected at baseline. Overall, these findings confirm the biological complexity of HER2-positive mCRC patients and emphasize the need for a deeper molecular insight to refine treatment strategies. Future studies should address not only the optimal sequencing of anti-HER2 therapies, but also whether the best approach lies in prioritizing single-agent molecularly targeted therapy, or in combining agents against multiple oncogenic drivers. Conclusions This meta-analysis confirms the efficacy of anti-HER2 therapies in patients with advanced, pretreated HER2-positive mCRC, demonstrating encouraging ORR even in later lines of treatment, with an encouraging safety profile. These results are consistent across most anti-HER2 regimens, with the notable exception of pertuzumab plus T-DM1, as tested in the HERACLES-B trial. It is reasonable to hypothesize that earlier use of anti-HER2 strategies, in less heavily pretreated patients could yield even greater benefits, particularly when combined with a chemotherapy backbone (as in the ongoing MOUNTAINEER-03 trial). Interestingly, anti-HER2 regimens appear to be especially active in all RAS/BRAF wild-type tumors, while limited activity has been observed in the presence of KRAS alterations or ERBB2 point mutations. In contrast, T-DXd has shown promising efficacy even in patients with activating point mutations or those previously treated with HER2-directed therapies, outperforming combinations such as trastuzumab plus pertuzumab in this context. Results from MOUNTAINEER-03, which may define a new standard of care in the first-line treatment, are eagerly awaited. In parallel, the expanding role of T-DXd in CRC warrants further investigation to determine the optimal therapeutic sequencing and best integration into current treatment algorithms. Supplementary Material Aknowledgments I would like to thank my colleagues from the Aviano Cancer Center. Contributor Information Simone Rota, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Paola Di Nardo, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Emma Zottarelli, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Fabiola Giudici, Unit of Cancer Epidemiology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Riccardo Vida, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Miriam Zilli, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Marco de Scordilli, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Luisa Foltran, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Arianna Fumagalli, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Michela Guardascione, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Elena Ongaro, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy. Fabio Puglisi, Department of Medical Oncology, CRO di Aviano—National Cancer Institute, IRCCS, Aviano, 33081, Italy; Department of Medicine (DMED), University of Udine, Udine, 33100, Italy. Author contributions Simone Rota (Conceptualization, Data curation, Investigation, Resources, Writing—original draft, Writing—review & editing), Paola Di Nardo (Methodology, Project administration, Supervision), Emma Zottarelli (Writing—original draft), Fabiola Giudici (Formal analysis, Methodology, Software), Riccardo Vida (Writing—original draft), Miriam Zilli (Writing—original draft), Marco de Scordilli (Writing—review & editing), Luisa Foltran (Writing—review & editing), Arianna Fumagalli (Writing—review & editing), Michela Guardascione (Writing—review & editing), Elena Ongaro (Writing—review & editing), and Fabio Puglisi (Project administration, Supervision, Writing—review & editing) Supplementary material Supplementary material is available at The Oncologist online. Funding This work was supported by the ‘Italian Ministry of Health—Ricerca Corrente.‘ Conflicts of interest F.P.: Consulting/advisory relationship: Astrazeneca, Daichii Sankyo, Menarini, MSD, Novartis, Pfizer, Roche Research Funding: Atrazeneca, Eisai, Roche Honoraria: Astrazeneca, Daichii Sankyo, Eli Lilly, Gilead, Menarini, MSD, Novartis, Pfizer, Roche. Data availability The data will be available upon request. References Associated Data Supplementary Materials Data Availability Statement The data will be available upon request.